Aktienanalyse zu CRISPR Therapeutics AG (CRSP)CRSPCRISPR Therapeutics AG

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

CRISPR Therapeutics AG (CRSP) is a good buy right now due to its recent positive trial results for CTX310, which showed a 79% reduction in ANGPTL3 levels and significant decreases in triglycerides and LDL cholesterol. The stock is currently priced at $57.72, with a forward P/E ratio of 23.36, indicating potential for growth as the company expands its pipeline. However, the main risk is the high insider selling activity, which has increased by 476.16% over the last month, suggesting caution from insiders.

6 analysts cover CRSP: 3 rate it Buy, 3 Hold and 0 Sell. The average price target is 78.89.